$ROIV

MANCHESTER KEITH S sold $49.4M of ROIV (indirect holdings)

MANCHESTER KEITH S sold 1,438,163 indirectly-held shares of Roivant Sciences Ltd. (ROIV) at an average of $34.32 ($33.92–$35.28, $49.35M total) across 5 trades over 2026-06-26 to 2026-06-30.

Original reporting
SEC EDGAR · MANCHESTER KEITH S
Published Jul 1, 2026, 12:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 1:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ROIV
Neutral
medium confidence
Mentioned
$ROIV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ROIVNeutralMed
01

Why it matters

A director’s ~$49.35M open-market sale can influence short-term sentiment, but it does not by itself change company fundamentals or guidance.

02

Market read

Traders may reassess ROIV positioning around insider-selling sentiment, while waiting for additional catalysts (earnings, trial updates, financing, or regulatory news).

03

What to watch

The transactions are spread across multiple days and are indirect holdings; traders should check for any concurrent option exercises/other insider buys in nearby filings before over-weighting the sale.

Relevance 7/10Novelty 6/10Timing: Filed 2026-06-30 after sales dated 2026-06-26 to 2026-06-30

Background

The article is an SEC Form 4 insider transaction disclosure for Roivant Sciences Ltd.

Company-level read

Ticker impact

$ROIVNeutralMedium confidence
Context

Roivant Sciences director Manchester Keith S sold 1,438,163 ROIV shares in open-market transactions for ~$49.35M, per Form 4.

Expected impact

Short-term: slight negative/neutral drift possible; medium-term: limited signal value unless follow-on filings show continued selling or a new catalyst emerges.

Evidence & confidence

The filing is primary-source and sizable, but the article notes no pre-arranged 10b5-1 plan, which increases interpretive uncertainty rather than providing a clear directional fundamental change.

Market effects

Limited sector read-through; this is company-specific insider activity rather than a biotech/sector-wide catalyst.

Minimal; US-listed issuer Form 4 typically affects single-name sentiment more than broader indices.

Low; no cross-border deal/regulatory action described.

Counterpoint

Without a 10b5-1 plan, the sale could reflect diversification/tax planning rather than a negative view on fundamentals.

Key entities

  • Roivant Sciences Ltd.

    Subject of the Form 4 insider sale; ticker ROIV.

  • Manchester Keith S

    Director who sold 1,438,163 shares in open-market transactions; indirect holdings.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ROIVMedAI 8/10

Transcript: Roivant Sciences Q1 2027 Earnings Conference Call - Roivant Sciences (NASDAQ:ROIV)

Roivant Sciences (ROIV) reported Q1 2026 results, highlighting a quiet quarter with progress in its pipeline, particularly brepocitinib's Phase 3 study. The company received a $950M settlement from Moderna and has ongoing litigation against Pfizer and BioNTech. Financially, ROIV reported $200M in R&D expenses, $100M in non-GAAP G&A expenses, and a cash position of nearly $4B. Management expects a busy second half with brepocitinib's launch and other pipeline updates.

Med

Roivant, the ‘inveterate drug hunters’, enters commercial era with Lisraya

Roivant Sciences, a biopharma company with a unique hub-and-spoke model, is transitioning into a commercial phase with the launch of Lisraya, an oral TYK2/JAK inhibitor for dermatomyositis. CEO Matt Gline aims to differentiate the company with a commercial portfolio, including Lisraya, Pulmovant’s mosliciguat, and Immunovant’s IMVT-1402. Leerink Partners estimates Lisraya could generate $7.9 billion in sales by 2035, with mosliciguat's expectations raised to $9.8 billion.

$ROIVMedAI 8/10

Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?

Roivant Sciences (ROIV) shares rose 17% after reporting positive Phase 2 results for mosliciguat, its experimental treatment for pulmonary hypertension. The drug met primary and secondary endpoints, reducing pulmonary vascular resistance by 56.3% and improving six-minute walk distance. J.P. Morgan estimates peak sales of $1.5B, though this is an analyst forecast. Roivant is now advancing to Phase 3 trials.